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Active pharmaceutical ingredients (APIs) are highly valuable, highly sensitive products resulting
from production processes with strict quality control specifications and regulations that are required
for the safety of patients. To ensure a profitable and growing pharmaceutical industry of significant
societal benefits and low environmental footprint, model-based tools are fundamental to advancing
the basic understanding, design, and optimization of pharmaceutical manufacturing processes in
accordance with the United Nations “2030 sustainable development goals”. Process analysis principles,
for instance, provide a better understanding of underlying pharmaceutical manufacturing mechanisms.
Model-based process design concepts facilitate the identification of optimal production and purification
pathways and configurations. Process monitoring and control strategies ensure low life-cycle costs
and provide new insights into critical failure modes and drug quality control issues.
The foregoing model-based concepts, and combinations of them, are key to exploring the
full potential of innovative, highly effective pharmaceutical manufacturing processes. These are
some of the grand challenges that can be tackled by process systems engineering (PSE), and they
have been catalyzed by an unprecedented advent of established methodologies and algorithmic
tools that are either available via open access environments or incorporated in commercial
software/databases for a plethora of purposes (thermodynamic and solubility modeling, fluid phase
equilibria, complex mixture thermophysical/mechanical property estimation, plant-wide simulation,
optimization and cost estimation). The respective advances achieved using such a diversity of enabling
computational technologies exemplify the Quality-by-Design (QbD) vision and its translation into
tangible artefacts and policies, illustrating how academia and industry respond to contemporary
challenges for high-quality, more affordable healthcare.
This Special Issue on “Model-Based Tools for Pharmaceutical Manufacturing Processes” intends
to curate novel advances in the development and application of model-based tools to address
ever-present challenges of the traditional pharmaceutical manufacturing practice as well as new
trends. As summarized below, the Special Issue provides a collection of nine papers on original
advances in the model-based process unit, system-level, QbD under uncertainty, and decision-making
applications of pharmaceutical manufacturing processes. The Special Issue is available online at
https://www.mdpi.com/journal/processes/special_issues/pharmaceutical_processes.
Processes 2020, 8, 49; doi:10.3390/pr8010049 www.mdpi.com/journal/processes
Processes 2020, 8, 49 2 of 4
1. Process Unit Studies
Before complex pharmaceutical manufacturing processes can be simulated holistically,
dedicated unit operations have to be studied first, including upstream and downstream processes.
Starting with the synthesis of APIs and relevant intermediates, enzymatic syntheses are of particular
interest as a greener, more economical, and efficient viable alternative to chemocatalytic processes.
For instance, pyrimidine-nucleoside phosphorylases are highly versatile enzymes used for the
production of pharmaceutically relevant intermediates. In “Dynamic Modelling of Phosphorolytic
Cleavage Catalyzed by Pyrimidine-Nucleoside Phosphorylase” [1], the conversion of deoxythymidine
and phosphate to deoxyribose-1-phosphate and thymine by a thermophilic pyrimidine-nucleoside
phosphorylase from Geobacillus thermoglucosidasius was modeled in detail and validated experimentally
including UV/Vis spectroscopy data. The resulting dynamic model might be used to identify optimal
operating conditions of the enzymatic synthesis process, and can be extended to multi-enzyme
reactions too.
Moreover, antibiotics are an essential group of biologics, and thus of interest in pharmaceutical
manufacturing. In “Dynamic Modelling and Optimisation of the Batch Enzymatic Synthesis of
Amoxicillin” [2], the batch enzymatic synthesis of the antibiotic amoxicillin, listed as a World
Health Organization (WHO) “Essential Medicine”, was modeled and optimized. While including
non-isothermal kinetics, the authors identified an optimal temperature profile that ensures high
product quality at minimum feedstock consumption.
In addition to synthesis problems, modeling of downstream processes has attracted much interest
in the last few decades. For instance, spray drying is a basic unit operation in pharmaceutical
manufacturing. In “Global Sensitivity Analysis of a Spray Drying Process” [3], a sensitivity analysis
study of a spray drying process is discussed. To quantify the impact of different but interacting process
parameters, a model-based global sensitivity analysis with a low computational cost was implemented,
contributing to QbD and the identification of critical process parameters. These essential parameters
of the process might be relevant for the development of future control strategies that can result in
significant robustness for the spray drying process.
2. System-Level Studies
Next, based on determined process unit models, system-level studies are crucial for a detailed
understanding of pharmaceutical manufacturing processes. The interaction between process units,
the identification of critical process parameters, and their impact on critical quality attributes of
pharmaceutical products are of key interest at the system level. For instance, when modeling the
flow of material in a continuous process of several unit operations (e.g., blending, granulation,
and tableting), the study of residence time distributions is the tool of choice. In “Explicit Residence
Time Distribution of a Generalised Cascade of Continuous Stirred Tank Reactors for a Description
of Short Recirculation Time (Bypassing)” [4], the so-called tanks-in-series model was generalized to
a cascade of n continuous stirred tank reactors with non-integer non-negative n. Therefore, the model
can describe short recirculation times (bypassing) without the need for complex reactor networks.
When part of a reactor network, the proposed model can be used to predict the response to upstream
setpoint changes and process fluctuations, i.e., providing insights at the system level.
The relevance of model-based studies of process-wide manufacturing lines is highlighted in
“Dynamic Flowsheet Model Development and Sensitivity Analysis of a Continuous Pharmaceutical
Tablet Manufacturing Process Using the Wet Granulation Route” [5]. In this study, the authors
implemented a dynamic flowsheet model of the ConsiGmaTM-25 line for continuous tablet
manufacturing, including determined models of various unit operations, i.e., feeders, blenders,
a twin-screw wet granulator, a fluidized bed dryer, a mill, and a tablet press. Based on the developed
dynamic flowsheet model, the liquid feed rate to the granulator, the air temperature, and the drying
time in the dryer were identified via global sensitivity analysis methods as critical process parameters
that affect the tablet properties most.
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3. Studies Under Uncertainty
QbD, an essential paradigm in pharmaceutical manufacturing, benefits from mathematical
models. Model imperfections, however, have to be considered seriously; that is, uncertainty
quantification and analysis are mandatory in model-based studies. This is particularly true when
making use of mathematical models to study the design space of manufacturing processes.
In “An Optimization-Based Framework to Define the Probabilistic Design Space of Pharmaceutical
Processes with Model Uncertainty” [6], the authors introduced two algorithms to analyze the design
space under uncertainties at low computational costs. The usefulness of the proposed probabilistic
design space implementations was benchmarked with pharmaceutical manufacturing problems,
including the Michael addition reaction as an industrial relevant case study.
In addition to uncertain model parameters and kinetics, batch-to-batch variations cause severe
difficulties in pharmaceutical manufacturing, affecting drug quality, clinical studies, and therapeutics
in equal measure. The joint effect of model imperfection and batch-to-batch variation is addressed
in “Robust Process Design in Pharmaceutical Manufacturing under Batch-to-Batch Variation” [7].
Considering a freeze-drying process, the authors used an efficient model-based concept to predict
optimal shelf temperature and chamber pressure profiles under batch-to-batch variation.
4. Decision-Making Studies
In addition to process analysis and optimization in pharmaceutical manufacturing, mathematical
models can support the decision-making process in identifying the best manufacturing concepts in
terms of reduced capital and operating costs. For instance, the best choice between pharmaceutical
manufacturing process alternatives is challenging and benefits considerably from algorithms and
decision-making tools. In “Online Decision-Support Tool “TECHoice” for the Equipment Technology
Choice in Sterile Filling Processes of Biopharmaceuticals” [8], the authors proposed a model-based
tool to support users in choosing their preferred technology according to their input of specific drug
production scenarios. The usefulness of the prototype tool was demonstrated successfully with the
study of equipment technologies in the sterile filling of biopharmaceutical manufacturing processes.
Modeling and simulation are a central part of research and development activities in the
pharmaceutical industry, but the evaluation of modeling and simulation return on investments is
difficult to quantify in advance. In “Show Me the Money! Process Modeling in Pharma from the
Investor’s Point of View” [9], the authors provide an algorithmic methodology that allows for the
development of detailed business studies. They discuss an easy-to-use methodology that can help
an investor evaluate an investment in modeling and simulation systematically.
The present Special Issue on “Model-Based Tools for Pharmaceutical Manufacturing Processes”
and several more on adjacent topics which have either appeared or will be featured in Processes (but also
in journals of similar scope and mission) signify the rapidly expanding importance of this research
field towards securing sophisticated healthcare solutions and improving accessibility to medication
for the ever-increasing and ageing global population. Publishing the fruits of academic, industrial,
and collaborative efforts to this end should serve as inspiration for new challenges to set and solutions
to achieve; our fervent hope is hence that PSE contributions will remain front and center in this quest.
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